JMX0312

JMX0312 (compound 17) potently inhibits the plaque formation of HAdV-5 in 293β5 cells, with an IC₅₀ of 0.18 μM; meanwhile, this compound exhibits low cytotoxicity in A549 cells, with a CC₅₀ of 120.0 μM, and thus has a selectivity index as high as 666.7^[1].
JMX0312 (50 μM; 48 h) completely inhibits the entry of HAdV-5 into A549 cells at a concentration of 50 μM. The entry inhibition IC₅₀ in A549 cells is 2.23 μM, and the CC₅₀ is 120.0 μM^[1].
JMX0312 (50 μM) reduces the HAdV-5 viral titer in A549 cells by 989-fold^[1].
JMX0312 (50 μM; 45 min) does not inhibit the delivery of the HAdV-5 genome to the nucleus under the treatment condition of administration at a concentration of 50 μM with continuous action for 45 min during A549 cell infection^[1].
JMX0312 (50 μM; 24 h) does not significantly inhibit HAdV-5 DNA replication in A549 cells when administered at 25 μM for 24 h post-infection^[1].
JMX0312 potently inhibits the replication of HAdV-5 in A549 cells, with an IC₅₀ of 0.18 μM, a CC₅₀ of 120.0 μM, and a selectivity index of 666.7^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.